Overview

Atorvia’s purpose is to transform outcomes for patients with severe medical conditions. Our initial focus is acute kidney injury (AKI), a devastating condition which affects millions worldwide yet still lacks effective therapy. To address this crisis, we are developing a kidney-targeted peptide that prevents regulated cell death and kidney failure.

Leadership
  • Jane Lapon

    CEO

  • David Allinson

    CFO & Head of Business Development

  • Nermeen Varawalla MD

    Chair Clinical Advisory Group

  • Steven C. Borkan MD

    Associate Professor, Boston Medical Centre

See all alumni